Loading...
NPI 1538686597 · Orange, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Genentox Laboratories LLC is a clinical medical laboratory provider located in Orange, California. This profile covers 60 Medicare and 76 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Genentox Laboratories LLC |
| Address | 744 N Eckhoff St Ste 150 |
| City | Orange |
| State | CA |
| ZIP | 92868 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 29, 2017 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $6.9M |
| Medicare | $6.1M |
GENENTOX LABORATORIES LLC is operating primarily as a high-volume molecular diagnostic laboratory focused on SARS-CoV-2 and other amplified nucleic acid tests: its top Medicare and Medicaid revenue codes are dominated by molecular infectious-agent detection CPT/HCPCS (notably U0003, 87635, 87798, U0005 and related multiplex respiratory codes), and many high-volume entries reference amplified probe or multiplex nucleic acid techniques. The code mix indicates an operational model centered on large-scale COVID-19 testing throughput plus multiplex respiratory panels and definitive drug testing services.
Revenue concentration is extreme in both payers and particularly concentrated in a few COVID-related codes: the precomputed top-3 Medicare codes account for 48.0% of Medicare revenue and the top-3 Medicaid codes account for 68.9% of Medicaid revenue. This shows the provider’s financials are heavily dependent on a small set of molecular testing services, with Medicaid even more concentrated.
In absolute scale the provider’s Medicaid and Medicare revenue are comparable but Medicaid is slightly larger: total Medicare revenue is $6.1M while total Medicaid revenue is $6.9M, so the business serves both payers materially rather than being single-payer dependent. The similar magnitudes suggest the lab contracts and billing operations span public payers and likely support broad population testing across both beneficiary groups.
GENENTOX is a dominant outlier nationally on several specific Medicare COVID test codes: for Medicare claims the provider ranks #3 nationally for 87635 (100th percentile; extreme outlier) and ranks very high for U0003 and U0005 (both described as extreme outliers and near the 99th percentile). These ranks indicate the lab is a national-scale high-volume performer for certain SARS-CoV-2 assays rather than a typical regional participant.
State-level competitive standing for Medicaid similarly shows strong concentration in COVID testing: the provider ranks #11 in-state for 87635 (99th percentile; extreme outlier) and #2 in-state for G2024 (98th percentile; extreme outlier), while U0003 is at the 95th percentile in-state. Those rankings show GENENTOX is among the largest Medicaid SARS-CoV-2 specimen processors in California for several fee lines, making it a significant in-state player for pandemic-era testing services.
Beyond SARS-CoV-2 assays, the provider also reports sizeable volumes of multiplex respiratory panels and definitive drug testing: Medicare lines include 87636, 87637, 87502 and G0483 among the top codes, and Medicaid lists similar multiplex respiratory codes plus G0483. These non-COVID codes suggest ancillary service lines (multiplex viral panels and definitive toxicology) that diversify test offerings, though they contribute a smaller share of total revenue.
Tenure information shows the provider’s Medicare NPI was enumerated on 2017-08-29 (~9 years ago), indicating the lab has been in the federal billing system for multiple years prior to the COVID-era surge. This tenure supports capacity to scale up high-throughput testing once demand surged.
Several codes are flagged as extreme outliers or high-percentile both nationally and in-state (for example, U0003, U0005, 87635 and G2024), which is consistent with a diagnostic lab that handled high COVID testing volume; these labels should be interpreted as statistical volume outliers (very far above typical provider counts) rather than clinical characterization. The pattern of multiple outlier codes concentrated on amplified nucleic acid techniques underscores specialization in high-throughput molecular diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
60 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 18,630 | $70 | $1.4M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 19,560 | $50 | $978K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 16,400 | $30 | $557.6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 18,560 | $30 | $463.9K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 18,320 | $30 | $458.1K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 2,110 | $140 | $296K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 3,120 | $90 | $292.9K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 7,370 | $30 | $250.6K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 1,760 | $140 | $246.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 6,060 | $30 | $206.2K |
Showing 1–10 of 60
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 60 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
60 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 26 | 70 | 360 | $240 | $427.9K |
| 87798 | 21 | 110 | 1,340 | $30 | $338.2K |
| U0003 | 6 | 130 | 730 | $70 | $246.4K |
| 87150 | 8 | 30 | 1,690 | $30 | $222.6K |
| G2023 | 62 | 90 | 1,030 | $20 | $110.9K |
| U0005 | 6 | 150 | 780 | $20 | $75.1K |
| 87481 | 10 | 100 | 270 | $30 | $72.7K |
| 87636 | 5 | 90 | 40 | $140 | $70.6K |
| 80307 | 35 | 150 | 220 | $60 | $69.2K |
| 87631 | 12 | 40 | 140 | $140 | $63.8K |
Showing 1–10 of 60
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
76 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 52,350 | $60 | $3.3M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 35,420 | $20 | $814.7K |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen… | 32,430 | $20 | $616.2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 29,320 | $20 | $469.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 18,930 | $20 | $340.7K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 5,430 | $50 | $287.8K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 5,370 | $40 | $188K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 4,800 | $30 | $153.7K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 2,860 | $40 | $114.4K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 1,980 | $50 | $95.1K |
Showing 1–10 of 76
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
76 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 42 | 100 | 520 | $120 | $2.4M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 37 | 750 | 950 | $50 | $890K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 42 | 250 | 800 | $110 | $625.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 322 | 660 | 1,490 | $30 | $417.2K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 53 | 280 | 730 | $90 | $315.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 143 | 290 | 220 | $210 | $268.3K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 812 | 1,140 | 530 | $20 | $195.6K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 892 | 1,270 | 450 | $20 | $183.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 984 | 1,720 | 1,360 | $10 | $165.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 42 | 500 | 530 | $20 | $128.1K |
Showing 1–10 of 76
Other providers in the same ZIP code as Genentox Laboratories LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.